←
Jason Colasanti, PhD728 posts
Jason Colasanti, PhD avatar

Jason Colasanti, PhD

@JasonColasanti

Engineering AI for healthcare, aging, and longevity | Prev: Sci Advisor @VitaDAO; research @Aptelab

◷ Joined September 2020▧ 9 Photos and videos
Ben Shenhar avatar
⟳ Jason Colasanti, PhD retweeted
Ben Shenhar@BShenhar·Jan 29

Our new paper on reassessing the heritability of human lifespan is out in @ScienceMagazine! 🧬 For decades, the consensus has been that genetics explains just 20–25% of lifespan differences. We found that after accounting for extrinsic mortality, that number jumps to ~50%. A 🧵

Post attachment
Agingdoc🩺Dr David Barzilai🔔MD PhD MS MBA DipABLM avatar
⟳ Jason Colasanti, PhD retweeted
Agingdoc🩺Dr David Barzilai🔔MD PhD MS MBA DipABLM@agingdoc1·12 Dec 2025

Randomized, placebo-controlled, double-blind clinical trial on the contributions of vitamin D in the control of cardiovascular risk factors, depressive symptoms and suicide risk Authors: "Weekly administration of 50,000 IU of vitamin D for six months proved effective in reducing depressive symptoms and suicide risk while improving cardiovascular health markers, highlighting its promise as an accessible, low-cost adjunctive therapy in psychiatric and primary care settings." sciencedirect.com/science/ar…

Aging Science News avatar
⟳ Jason Colasanti, PhD retweeted
Aging Science News@AgingBiology·26 Nov 2025

Organ-specific proteomic aging clocks predict disease and longevity across diverse populations nature.com/articles/s43587-0…

Karl Pfleger avatar
⟳ Jason Colasanti, PhD retweeted
Karl Pfleger@KarlPfleger·23 Nov 2025

Infographics are poor ways to track aging biotechs. AgingBiotech.info/companies has a more comprehensive list w/ category + details like pipeline status, $ raised, # employees. Fully sortable/filterable. 289 biotechs currently & 180+ more on the to-be-considered tab (vs 75 above).

Laura Minquini avatar
⟳ Jason Colasanti, PhD retweeted
Laura Minquini@LauraMinquini·22 Nov 2025

One of the saddest realizations being in tech is that a lot of capital allocation happens on vibes, networks, fomo, and marketing. I have said this to a lot of our researchers; the best and most rigorous science does not necessarily win. The downstream effects of that is that we probably have a very big graveyard of real scientific innovation (actual cures, therapeutics and more), while questionable projects have millions.

This tweet is unavailable

Logan Thrasher Collins avatar
⟳ Jason Colasanti, PhD retweeted
Logan Thrasher Collins@LoganTCollins·7 Oct 2025

An interesting perspective. What regulatory pathway will 3D printed organs take to along the way to the market? Will there be restrictions on IP in the context of 3D printed organs? This article explores these questions. bigthink.com/health/3d-print…

Agingdoc🩺Dr David Barzilai🔔MD PhD MS MBA DipABLM avatar
⟳ Jason Colasanti, PhD retweeted
Agingdoc🩺Dr David Barzilai🔔MD PhD MS MBA DipABLM@agingdoc1·4 Oct 2025

Anti Aging Breakthrough: Stem Cells Reverse Signs of Aging in Monkeys. Buzzing lay article (Titled above & image): nad.com/news/anti-aging-brea… Original Study: x.com/agingdoc1/status/19739… 🤔Author interpretation: "This study provides initial evidence that genetically modified human mesenchymal progenitors can slow primate aging, highlighting the therapeutic potential of regenerative approaches in combating age-related health decline." Share your data-driven📊 comments below 👇

Post attachment

Senescence-resistant human mesenchymal progenitor cells counter aging in primates 🐒 👉 “This study provides initial evidence that genetically modified human mesenchymal progenitors can slow primate aging” cell.com/cell/fulltext/S0092…

Post attachment
Alex Colville avatar
⟳ Jason Colasanti, PhD retweeted
Alex Colville@AlexJColville·30 Jul 2025

Introducing the 1st annual pharma aging report card!! The race is on to see who will positively transform humanity and in the process unlock a bigger market than obesity.

Post attachment

Pharma talks a big game about “healthy aging.” Few are actually building toward it. We ran the numbers so you don't have to: age1’s 2025 1st Annual Pharma Aging Report Card, ranking 11 global players on their commitment to the longevity field, is now live. librariesforthefuture.bio/p/…

VitaDAO 💛 avatar
⟳ Jason Colasanti, PhD retweeted
VitaDAO 💛@vita_dao·8 Jul 2025

Gero, backed by the VitaDAO community, just landed a $1B+ deal with Chugai (Roche)! Their AI finds the root causes of age-related diseases → Chugai develops antibody drugs from these discoveries. Big leap forward for longevity research 🧬 biospace.com/business/roches…

ARPA-H avatar
⟳ Jason Colasanti, PhD retweeted
ARPA-H@ARPA_H·10 Jul 2025

NEW: No technology currently exists to repair damaged brain tissue and fully restore lost function. FRONT aims to enable millions with what is considered permanent brain damage to regain lost functions, including motor control, vision, and speech. arpa-h.gov/news-and-events/a…

zack chiang avatar
⟳ Jason Colasanti, PhD retweeted
zack chiang@z_chiang·29 May 2025

The peer-reviewed version of expansion in situ genome sequencing is now out in Science! The news is bittersweet – when we first revealed this last September, I never guessed it would be my final paper in academia, but a lot has changed. A few parting thoughts:

Post attachment